Tanja Stenger1, Alexandra Ledo2, Clemens Ziller1, David Schub2, Tina Schmidt2, Martin Enders3, Barbara C Gärtner4, Martina Sester2, Tim Meyer1. 1. Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, GERMANY. 2. Department of Transplant and Infection Immunology, Saarland University, Homburg/Saar, GERMANY. 3. Laboratory Prof. G. Enders and Partners and Institute of Virology, Infectious Diseases and Epidemiology e.V., Stuttgart, GERMANY. 4. Institute of Medical Microbiology and Hygiene, Saarland University, Homburg/Saar, GERMANY.
Abstract
OBJECTIVES:Influenza vaccination was used to assess whether induction of immunity or side effects are influenced by the timing of the last training session before vaccination. METHODS:Forty-five healthy athletes (36 male, 23 ± 8 yr, ≥5 training sessions per week, predominantly national competition level) were vaccinated with the tetravalent influenza vaccine; blood samples were collected immediately before and 1, 2, and 26 wk after vaccination. Athletes were randomly assigned to vaccination within 2 h after the last training session versus after 24-26 h. Influenza-specific T cells were quantified after stimulation with the vaccine based on intracellular cytokine staining. Antibodies (IgA, IgG, IgM) were quantified by enzyme-linked immunosorbent assay and neutralization assay. Participants documented resulting side effects and training restrictions using a standardized diary. RESULTS: Both groups showed an increase in influenza-reactive CD4 T-cell levels, which peaked 1 wk after vaccination (fold changes to baseline; median (interquartile range), 3.7 (3.0-5.4; P < 0.001) in the 2-h group; 4.6 (2.8-7.4; P < 0.001) in the 26-h group) with no difference between groups (P = 0.52). Influenza-specific antibodies showed a significant increase after vaccination in both groups (at least 1.4-fold, each P < 0.001, no group differences; P = 0.24-0.97 for different antibody types). Only antibodies toward the Brisbane strain showed a trend toward significant differences in neutralization titers between groups (4-fold (2-17.8) in the 2-h group, 16-fold (4-32.9) in the 26-h group; P = 0.06), whereas other specificities did not differ (P = 0.16-0.72). No intergroup differences were found for side effects; no athlete reported a loss of training time due to the vaccination or its side effects. CONCLUSION: Infection prophylaxis in elite athletes by influenza vaccination seems to be effective and safe. Timing of vaccination after prior training does not seem to require specific constraints.
RCT Entities:
OBJECTIVES: Influenza vaccination was used to assess whether induction of immunity or side effects are influenced by the timing of the last training session before vaccination. METHODS: Forty-five healthy athletes (36 male, 23 ± 8 yr, ≥5 training sessions per week, predominantly national competition level) were vaccinated with the tetravalent influenza vaccine; blood samples were collected immediately before and 1, 2, and 26 wk after vaccination. Athletes were randomly assigned to vaccination within 2 h after the last training session versus after 24-26 h. Influenza-specific T cells were quantified after stimulation with the vaccine based on intracellular cytokine staining. Antibodies (IgA, IgG, IgM) were quantified by enzyme-linked immunosorbent assay and neutralization assay. Participants documented resulting side effects and training restrictions using a standardized diary. RESULTS: Both groups showed an increase in influenza-reactive CD4 T-cell levels, which peaked 1 wk after vaccination (fold changes to baseline; median (interquartile range), 3.7 (3.0-5.4; P < 0.001) in the 2-h group; 4.6 (2.8-7.4; P < 0.001) in the 26-h group) with no difference between groups (P = 0.52). Influenza-specific antibodies showed a significant increase after vaccination in both groups (at least 1.4-fold, each P < 0.001, no group differences; P = 0.24-0.97 for different antibody types). Only antibodies toward the Brisbane strain showed a trend toward significant differences in neutralization titers between groups (4-fold (2-17.8) in the 2-h group, 16-fold (4-32.9) in the 26-h group; P = 0.06), whereas other specificities did not differ (P = 0.16-0.72). No intergroup differences were found for side effects; no athlete reported a loss of training time due to the vaccination or its side effects. CONCLUSION: Infection prophylaxis in elite athletes by influenza vaccination seems to be effective and safe. Timing of vaccination after prior training does not seem to require specific constraints.
Authors: Helena Batatinha; Forrest L Baker; Kyle A Smith; Tiffany M Zúñiga; Charles R Pedlar; Shane C Burgess; Emmanuel Katsanis; Richard J Simpson Journal: J Appl Physiol (1985) Date: 2021-12-09
Authors: Miguel Junior Sordi Bortolini; Bernardo Petriz; José Roberto Mineo; Rafael de Oliveira Resende Journal: Int J Environ Res Public Health Date: 2022-02-07 Impact factor: 3.390
Authors: Jarosław Krzywański; Tomasz Mikulski; Hubert Krysztofiak; Andrzej Pokrywka; Tomasz Sobierajski; Marcel Młyńczak; Aleksandra Piechuta; Ernest Kuchar Journal: J Sci Med Sport Date: 2022-10-12 Impact factor: 4.597
Authors: Tim Meyer; Dietrich Mack; Katrin Donde; Oliver Harzer; Werner Krutsch; Annika Rössler; Janine Kimpel; Dorothee von Laer; Barbara C Gärtner Journal: Br J Sports Med Date: 2020-09-24 Impact factor: 13.800